Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Erasca, Inc. publishes a filing, an earnings call transcript or a press release.

Get ERAS alerts

About Jonathan Lim

Jonathan Lim is recorded as Chairman and CEO at Erasca, Inc. (ERAS) and Board Member at Maze Therapeutics, Inc. (MAZE) since January 1, 2019. The newest filing on record that lists Jonathan Lim as CEO at Erasca, Inc. (ERAS) is dated April 28, 2026. The newest filing on record that lists Jonathan Lim as Board Member at Maze Therapeutics, Inc. (MAZE) is dated April 28, 2026. The proxy statement of Erasca, Inc. reports total compensation of $4,298,838 for Jonathan Lim in fiscal 2025, including a base salary of $670,400. Disclosed compensation is on record for 6 fiscal years. Jonathan Lim has spoken on 3 investor events across 1 company, most recently for Erasca, Inc. on November 18, 2026. Erasca, Inc. is classified in the Biotechnology industry within the Healthcare sector. Maze Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Erasca, Inc. includes David Chacko (CFO), Ebun S. Garner (General Counsel), Alexander W. Casdin (Board Member) and 7 others.

Jonathan Lim on recent calls

“Yeah, Erasca is a company whose mission is to erase cancer and eradicate RAS-driven cancer. Our pipeline consists of two RAS-targeting agents. The lead program is ERAS-15, which is a pan-RAS molecular glue.”
CEO, Jefferies Global Healthcare Conference in London ·
“So maybe a good place to start is just to provide a quick intro to the company and your pipeline for those who might be newer to the story. Yeah, RASCA was formed in 2018 around the premise of erasing cancer and eradicating RAS-driven cancer.”
Chairman, Guggenheim 3rd Annual Healthcare Innovation Conference ·
“This is a potential best-in-class pan-ras molecular glue. It's one that is in a Phase I dose escalation study called Aurorus I. And going into that program, preclinical activity looks really interesting because this is a molecule that's been optimized on both potency as well as PK.”
Chairman, Morgan Stanley 24th Annual Global Healthcare Conference ·

Affiliation history

Company network

Leadership on record at Erasca, Inc.

Leadership on record at Maze Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Erasca, Inc. (ERAS) $670,400 $4,298,838
2024 Erasca, Inc. (ERAS) $644,600 $3,894,032
2023 Erasca, Inc. (ERAS) $622,800 $5,407,446
2022 Erasca, Inc. (ERAS) $593,100 $7,523,335
2021 Erasca, Inc. (ERAS) $497,846 $850,234
2020 Erasca, Inc. (ERAS) $300,000 $1,964,696

Recent activity